Jaguar Animal Health

Jaguar Animal Health Plant-based 🌱 gastrointestinal products for dogs, production animals, and equines.

Jaguar Animal Health supports the health and well-being of dogs, production animals, and equines. Our plant-based gastrointestinal products include Canalevia®-CA1, the only FDA conditionally approved drug to treat chemotherapy-induced diarrhea (CID) in dogs.

Address

200 Pine Street, Suite 600
San Francisco, CA
94104

Website

Alerts

Be the first to know and let us send you an email when Jaguar Animal Health posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Jaguar Animal Health:

Shortcuts

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram

Our Story

Official account for the Animal Health Segment of Jaguar Health, Inc. In conjunction with Napo Pharmaceuticals*, our new subsidiary, Jaguar Health is focused on developing and commercializing a range of first-in-class gastrointestinal prescription products for humans and animals, as well as non-prescription gastrointestinal products for animals. *On Monday, July 31, the merger of Jaguar Animal Health and Napo Pharmaceuticals became effective. Napo focuses on the development and commercialization of proprietary gastrointestinal pharmaceuticals for the global human marketplace from sustainably derived plants used traditionally in rainforest areas. As a result of the merger, Jaguar’s name is now Jaguar Health, Inc., and Napo is a wholly-owned subsidiary of Jaguar, focused on the continuing commercialization of its Mytesi® (crofelemer) product, which is approved by the U.S. FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.